Table 4.

Univariate and multivariate analyses of distant metastatic free survival in the training set.

Characteristic	Univariate analysis		Multivariate Cox regression analysis
	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Age (years)	0.709 (0.472–1.064)	0.097
Histological type	0.675 (0.340–1.340)	0.261
Tumor grade	1.179 (0.886–1.567)	0.258
T stage	1.469 (1.313–1.908)	0.004*	1.031 (0.779–1.364)	0.832
N stage	1.883 (1.581–2.242)	0.000*	1.783 (1.447–2.196)	0.000*
Clinical stage	2.691 (1.952–3.708)	0.000*
Molecular subtype	0.933 (0.801–1.087)	0.374
ER	1.252 (0.783–2.001)	0.348
PR	0.934 (0.619–1.408)	0.744
HER2	1.098 (0.714–1.690)	0.669
Ki67	1.591 (1.003–2.524)	0.049*	1.480 (0.932–2.353)	0.097
Adjuvant chemotherapy	2.195 (1.065–4.526)	0.033*	1.579 (0.749–3.328)	0.230
Endocrine Therapy	1.403 (0.923–2.131)	0.113
Radiotherapy	2.100 (1.403–3.143)	0.000*	1.101 (0.700–1.732)	0.678
Target Therapy	1.011 (0.467–2.189)	0.977
SIS group	1.557 (1.035–2.341)	0.033*	1.521 (1.009–2.293)	0.045*

^*P < 0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; SIS, Systemic inflammation score.